MBB Public Markets I LLC Makes New Investment in Hologic, Inc. (NASDAQ:HOLX)

MBB Public Markets I LLC bought a new position in shares of Hologic, Inc. (NASDAQ:HOLX) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 17,665 shares of the medical equipment provider’s stock, valued at approximately $1,312,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Deerfield Management Company L.P. Series C acquired a new position in shares of Hologic during the 2nd quarter worth approximately $1,020,000. Earnest Partners LLC grew its position in shares of Hologic by 3.5% during the 2nd quarter. Earnest Partners LLC now owns 1,878,206 shares of the medical equipment provider’s stock worth $139,457,000 after purchasing an additional 64,178 shares in the last quarter. APG Asset Management N.V. grew its position in shares of Hologic by 2.2% during the 2nd quarter. APG Asset Management N.V. now owns 360,093 shares of the medical equipment provider’s stock worth $24,947,000 after purchasing an additional 7,828 shares in the last quarter. AQR Capital Management LLC grew its position in shares of Hologic by 1.5% during the 2nd quarter. AQR Capital Management LLC now owns 565,955 shares of the medical equipment provider’s stock worth $42,022,000 after purchasing an additional 8,441 shares in the last quarter. Finally, Squarepoint Ops LLC grew its position in shares of Hologic by 251.9% during the 2nd quarter. Squarepoint Ops LLC now owns 58,880 shares of the medical equipment provider’s stock worth $4,372,000 after purchasing an additional 97,634 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Trading Up 0.9 %

NASDAQ HOLX opened at $80.82 on Monday. The company has a market cap of $18.86 billion, a price-to-earnings ratio of 41.23, a price-to-earnings-growth ratio of 2.58 and a beta of 0.98. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $84.67. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The business’s fifty day moving average is $81.08 and its 200 day moving average is $77.29.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. During the same period last year, the firm posted $0.93 earnings per share. The business’s revenue for the quarter was up 2.7% on a year-over-year basis. As a group, sell-side analysts expect that Hologic, Inc. will post 4.09 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Brandon Schnittker sold 476 shares of the firm’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the transaction, the insider now owns 3,735 shares of the company’s stock, valued at $310,415.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Brandon Schnittker sold 476 shares of the business’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the sale, the insider now owns 3,735 shares of the company’s stock, valued at $310,415.85. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Benjamin Jordan Cohn sold 5,093 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the transaction, the insider now directly owns 10,476 shares of the company’s stock, valued at $858,927.24. The disclosure for this sale can be found here. Insiders have sold 18,280 shares of company stock valued at $1,469,973 in the last ninety days. 1.75% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

HOLX has been the topic of several recent analyst reports. StockNews.com lowered shares of Hologic from a “strong-buy” rating to a “buy” rating in a report on Friday. Needham & Company LLC reissued a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research note on Tuesday, September 17th. Royal Bank of Canada restated a “sector perform” rating and set a $82.00 target price on shares of Hologic in a research note on Friday, August 16th. Stephens reiterated an “overweight” rating and issued a $92.00 price target on shares of Hologic in a research note on Tuesday, July 30th. Finally, Evercore ISI boosted their price target on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a report on Tuesday, July 30th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $87.60.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.